Related Experiment Video
Updated: Jan 6, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor
Ling-Juan Huang1,2,3, Ying Shen1, Ju Bai1
1Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background:
The aim of this study was to detect the expression of long noncoding RNA small nucleolar RNA host gene 18 (SNHG18) andsemaphorin 5A (SEMA5A) genes in multiple myeloma (MM) patients and to explore the correlation of the expression of these genes with the clinical characteristics and prognosis of MM patients.
Methods:
Forty-seven newly diagnosed MM, 18 complete remission MM, 13 refractory/relapse MM, and 22 iron deficiency anemia (serving as control) samples were extracted at the Department of Hematology, Second Affiliated Hospital of Xian Jiaotong University between January 2015 and December 2016. The clinical features of the MM patients are summarized. Real-time quantitative PCR was performed to analyze the relative expression levels of the SNHG18 and SEMA5Agenes. The clinical characteristics and overall survival (OS) of the MM patients were statistically analyzed while measuring different levels of SNHG18 and SEMA5Agene expression. At the same time, the correlation between the expression of SNHG18 and SEMA5A was also analyzed.
Results:
The analysis confirmed that SNHG18 and its possible target gene SEMA5A were both highly expressed in newly diagnosed MM patients. After analyzing the clinical significance of SNHG18 and SEMA5A in MM patients, we found that the expression of SNHG18 and SEMA5A was related to the Durie-Salmon (DS), International Staging System (ISS), and Revised International Staging System (R-ISS) classification systems, and the Mayo Clinic Risk Stratification for Multiple Myeloma (mSMART; p < 0.05). Moreover, we observed a significant difference in OS between the SNHG18/SEMA5A high expression group and the low expression group. We found a positive correlation between SNHG18 and SEMA5A expression (r = 0.709, p < 0.01). Surprisingly, the expected median OS times of both the SNHG18 and SEMA5Ahigh expression groups were significantly decreased, which was in contrast to those of both the SNHG18 and SEMA5Alow expression groups and the single-gene high expression group (p < 0.05).
Conclusion:
High expression of both SNHG18 and SEMA5A is associated with poor prognosis in patients with MM.
Insights
High expression of long noncoding RNA SNHG18 and SEMA5A indicates a poor prognosis for multiple myeloma (MM) patients. This finding suggests these genes could be potential biomarkers for MM progression and patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Gene Expression Analysis
Background:
- Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled plasma cell proliferation.
- Understanding the molecular mechanisms underlying MM progression is crucial for developing effective therapeutic strategies.
- Long noncoding RNAs (lncRNAs) and their target genes play significant roles in various cancers, including MM.
Purpose of the Study:
- To investigate the expression levels of lncRNA SNHG18 and its potential target gene SEMA5A in multiple myeloma patients.
- To explore the correlation between SNHG18 and SEMA5A gene expression and the clinical characteristics of MM.
- To assess the relationship between SNHG18 and SEMA5A expression and the overall survival (OS) of MM patients.
Main Methods:
- Analysis of gene expression in newly diagnosed MM, complete remission MM, refractory/relapse MM, and iron deficiency anemia control groups.
- Utilized Real-time quantitative PCR (qPCR) to determine relative expression levels of SNHG18 and SEMA5A.
- Statistical analysis of clinical features, staging systems (DS, ISS, R-ISS, mSMART), and overall survival in relation to gene expression levels.
Main Results:
- SNHG18 and SEMA5A were found to be highly expressed in newly diagnosed MM patients.
- Gene expression levels correlated significantly with established MM staging systems (DS, ISS, R-ISS, mSMART).
- High co-expression of SNHG18 and SEMA5A was associated with significantly reduced overall survival (OS) and a positive correlation (r=0.709, p<0.01) between the two genes.
Conclusions:
- Elevated expression of both SNHG18 and SEMA5A is linked to a poorer prognosis in multiple myeloma.
- These genes may serve as potential biomarkers for predicting MM patient outcomes.
- Further research into the functional roles of SNHG18 and SEMA5A in MM pathogenesis is warranted.
Related Concept Videos
lncRNA - Long Non-coding RNAs
MicroRNAs
Non-LTR Retrotransposons
Abnormal Proliferation
The Nucleolus
RNA Splicing
